US pharmaceutical giant Pfizer has entered into a global licencing agreement with Innovent Biologics, a Chinese biopharmaceutical company listed on the Hong Kong Stock Exchange (HKEX), with the aim of accelerating the development of innovative oncology medicines, according to a May 28 announcement.
¬ Haymarket Media Limited. All rights reserved.
